1. Home
  2. EVO vs XERS Comparison

EVO vs XERS Comparison

Compare EVO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.06

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.40

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVO
XERS
Founded
1993
2005
Country
Germany
United States
Employees
4553
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
934.1M
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EVO
XERS
Price
$3.06
$6.40
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$7.00
$10.83
AVG Volume (30 Days)
95.4K
1.4M
Earning Date
04-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
N/A
$49,590,000.00
Revenue This Year
$1.37
$34.37
Revenue Next Year
$10.05
$22.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
142.67
52 Week Low
$2.31
$4.30
52 Week High
$4.80
$10.08

Technical Indicators

Market Signals
Indicator
EVO
XERS
Relative Strength Index (RSI) 52.19 57.52
Support Level $2.88 $6.26
Resistance Level $3.78 $7.21
Average True Range (ATR) 0.12 0.27
MACD -0.01 0.04
Stochastic Oscillator 33.33 50.21

Price Performance

Historical Comparison
EVO
XERS

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: